Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Neurochem Res ; 43(6): 1171-1181, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29671235

ABSTRACT

A number of neurotransmitter systems have been implicated in contributing to the pathology of mood disorders, including those of dopamine (DA), serotonin (5-HT), norepinephrine (NE) and γ-aminobutyric acid (GABA). Rapid eye movement sleep deprivation (REMSD) alters most of the neurotransmitters, which may have adverse behavioural changes and other health consequences like mania and other psychiatric disorders. The exact role of REMSD altered neurotransmitter levels and the manner in which emerging consequences lead to mania-like behaviour is poorly understood. Thus, we sought to verify the levels of neurotransmitter changes after 48, 72 and 96 h of REMSD induced mania-like behaviour in mice. We performed modified multiple platform (MMP) method of depriving the REM sleep and one group maintained as a control. To measure the hyperactivity through locomotion, exploration and behavioural despair, we performed the Open Field Test (OFT) and the Forced Swim Test (FST). Quantitative determinations of DA, 5-HT, NE and GABA concentrations in four distinct brain regions (cerebral cortex, hippocampus, midbrain, and pons) were determined by the spectrofluorimetric method. These experiments showed higher locomotion and increased swimming, struggling/climbing and decreased mobility among REMSD animals as well as disrupted concentrations of the majority of the studied neurotransmitters during REMSD. Our study indicated that REMSD results in mania-like behaviour in mice and associated disruption to neurotransmitter levels, although the exact mechanisms by which these take place remain to be determined.


Subject(s)
Bipolar Disorder/metabolism , Brain/metabolism , Neurotransmitter Agents/metabolism , Sleep Deprivation/metabolism , Sleep, REM/physiology , Animals , Bipolar Disorder/etiology , Bipolar Disorder/psychology , Dopamine/metabolism , Male , Mice , Norepinephrine/metabolism , Random Allocation , Serotonin/metabolism , Sleep Deprivation/complications , Sleep Deprivation/psychology
2.
Biol Trace Elem Res ; 160(3): 409-17, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25035188

ABSTRACT

Manic episode in bipolar disorder (BD) was evaluated in the present study with supplementation of omega-3 fatty acids in combination with aripiprazole and lithium on methylphenidate (MPD)-induced manic mice model. Administration of MPD 5 mg/kg bw intraperitoneally (i.p.) caused increase in oxidative stress in mice brain. To retract this effect, supplementation of omega-3 fatty acids 1.5 ml/kg (p.o.), aripiprazole 1.5 mg/kg bw (i.p.), and lithium 50 mg/kg bw (p.o) were given to mice. Omega-3 fatty acids alone and in combination with aripiprazole- and lithium-treated groups significantly reduced the levels of superoxide dismutase (SOD), catalase (CAT), and lipid peroxidation products (thiobarbituric acid reactive substances) in the brain. MPD treatment significantly decreased the reduced glutathione (GSH) level and glutathione peroxidase (GPx) activity, and they were restored by supplementation of omega-3 fatty acids with aripiprazole and lithium. There is no remarkable difference in the effect of creatine kinase (CK) activity between MPD-induced manic model and the treatment groups. Therefore, our results demonstrate that oxidative stress imbalance and mild insignificant CK alterations induced by administration of MPD can be restored back to normal physiological levels through omega-3 fatty acids combined with lithium and aripiprazole that attributes to effective prevention against mania in adult male Swiss albino mice.


Subject(s)
Antimanic Agents/pharmacology , Antipsychotic Agents/pharmacology , Bipolar Disorder , Fatty Acids, Omega-3/pharmacology , Lithium Compounds/pharmacology , Oxidative Stress/drug effects , Piperazines/pharmacology , Quinolones/pharmacology , Animals , Aripiprazole , Bipolar Disorder/metabolism , Bipolar Disorder/pathology , Bipolar Disorder/prevention & control , Brain/metabolism , Brain/pathology , Brain Chemistry/drug effects , Disease Models, Animal , Glutathione/metabolism , Male , Mice , Oxidoreductases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...